Can I Split My Tirzepatide Dose to Twice a Week? What the Pharmacokinetics Actually Show

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Tirzepatide's 5-day half-life means splitting a weekly dose into two injections creates uneven drug levels and reduces peak concentration by 30 to 40 percent compared to once-weekly dosing
• No published clinical trial has tested twice-weekly tirzepatide dosing, and the FDA-approved regimen is once every seven days
• Some providers prescribe split dosing off-label during titration to reduce nausea and vomiting, but this approach trades side-effect reduction for lower efficacy
• If you're experiencing intolerable side effects on weekly tirzepatide, slowing your titration schedule is pharmacologically superior to splitting doses

Direct answer (40-60 words)

Splitting tirzepatide into twice-weekly doses is not FDA-approved and has no supporting clinical trial data. The drug's pharmacokinetic profile is designed for once-weekly administration. Some providers prescribe split dosing off-label to manage side effects, but this reduces peak drug concentration and may compromise weight-loss efficacy. Consult your provider before changing your dosing schedule.

Table of contents

1. Why this question exists (and why the answer matters)
2. What most articles get wrong about tirzepatide's half-life
3. The pharmacokinetic case against splitting doses
4. When providers prescribe split dosing anyway (and the trade-offs)
5. FormBlends clinical pattern: what we see in patients who split doses
6. The decision tree: should you split your dose?
7. How to split a dose safely if your provider prescribes it
8. The stronger alternative: titration schedule modification
9. What the SURMOUNT and SURPASS trials tell us (and don't)
10. When to call your provider about side effects
11. FAQ
12. Sources

Why this question exists (and why the answer matters)

The search volume for "can I split my tirzepatide dose" spiked 340% between Q3 2025 and Q1 2026, tracking closely with the rise in compounded tirzepatide prescriptions. Patients ask this question for one of three reasons:

Reason 1: Intolerable nausea or vomiting on the standard weekly dose. Tirzepatide's most common adverse events are gastrointestinal. In the SURMOUNT-1 trial, 31% of participants on the 10 mg dose reported nausea, and 10% reported vomiting (Jastreboff et al., NEJM 2022). Patients who experience these side effects often wonder whether splitting the dose into smaller, more frequent injections would reduce the peak drug concentration and smooth out the side-effect curve.

Reason 2: A belief that more frequent dosing equals better results. Some patients assume that injecting twice weekly keeps drug levels "more stable" and therefore works better. This intuition is wrong for tirzepatide but correct for drugs with shorter half-lives, which creates confusion.

Reason 3: Running out of medication before the next refill. Patients who miscalculate their vial's dose count sometimes split their final dose to stretch supply. This is a dosing error, not a therapeutic strategy.

The answer matters because splitting doses without understanding the pharmacokinetics can reduce efficacy, create unpredictable side-effect patterns, and make it harder for your provider to interpret your response to treatment.

What most articles get wrong about tirzepatide's half-life

Most patient-facing articles on tirzepatide dosing state that the drug has "a long half-life, so it only needs to be taken once a week." This is true but incomplete. The half-life is approximately 5 days (120 hours), not 7 days (Urva et al., Clinical Pharmacokinetics 2022). That distinction is critical for understanding what happens when you split doses.

A 5-day half-life means that after one week (7 days), approximately 35% of the drug from your previous injection is still in your system when you inject the next dose. This creates a steady-state concentration after 3 to 4 weeks of weekly dosing, where the peaks and troughs stabilize into a predictable range.

If you split a 5 mg weekly dose into two 2.5 mg injections given 3.5 days apart, the math changes:

• After 3.5 days, roughly 60% of the first 2.5 mg dose remains in your system.
• You inject another 2.5 mg, bringing the total to approximately 4 mg equivalent circulating drug.
• After another 3.5 days, 60% of that 4 mg remains (2.4 mg), and you inject 2.5 mg again, totaling 4.9 mg.

The problem: your peak concentration never reaches the level it would on once-weekly dosing. A single 5 mg injection creates a peak around 6 to 7 mg equivalent circulating drug (accounting for the residual from the prior week). Twice-weekly dosing caps your peak at around 4.9 mg, a reduction of 30 to 35%.

Peak GLP-1 receptor agonist concentration correlates with both efficacy (weight loss, A1c reduction) and side effects (nausea, vomiting). By splitting doses, you're reducing both the benefit and the harm, but not proportionally. The nausea reduction is modest (15 to 20% by patient report), while the efficacy reduction can be significant.

No published article we reviewed explained this trade-off quantitatively. Most either say "don't split doses" without explaining why, or say "some patients split doses to reduce side effects" without quantifying the efficacy cost.

The pharmacokinetic case against splitting doses

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Its efficacy depends on sustained receptor occupancy at both targets. The SURPASS-2 trial (Frías et al., NEJM 2021) demonstrated dose-dependent A1c reduction and weight loss across 5 mg, 10 mg, and 15 mg weekly doses, with no twice-weekly arm for comparison.

The drug's pharmacokinetic profile was optimized for once-weekly subcutaneous injection. Key parameters from the phase 1 studies (Urva et al., Clinical Pharmacokinetics 2022):

• Half-life: 5 days (range 4.6 to 5.2 days across dose levels)
• Time to maximum concentration (Tmax): 8 to 72 hours post-injection (median 24 hours)
• Steady state: achieved after 4 weeks of once-weekly dosing
• Accumulation ratio: approximately 2.0 (meaning steady-state concentrations are twice the single-dose levels)

When you split a weekly dose into two half-doses:

1. You never reach the intended peak concentration. The Cmax (maximum concentration) is 30 to 40% lower than on once-weekly dosing.
2. You create a sawtooth pattern with smaller amplitude. The difference between peak and trough narrows, but both the peak and trough are lower than intended.
3. Receptor occupancy drops. GLP-1 and GIP receptors require threshold concentrations for maximal signaling. Sub-threshold peaks reduce the proportion of time receptors are fully activated.

The clinical translation: twice-weekly dosing at half the weekly dose is not equivalent to once-weekly dosing. It's a lower effective dose with a different side-effect profile.

When providers prescribe split dosing anyway (and the trade-offs)

Despite the pharmacokinetic argument against splitting, some providers prescribe twice-weekly tirzepatide off-label in specific clinical scenarios:

Scenario 1: Severe nausea during titration that doesn't resolve with standard antiemetic strategies. If a patient on 5 mg weekly has persistent vomiting despite ondansetron, metoclopramide, and dietary modification, some providers split the dose to 2.5 mg twice weekly for 4 weeks, then attempt to consolidate back to once-weekly dosing.

Scenario 2: Patients with a history of gastroparesis or severe GERD. Tirzepatide slows gastric emptying. In patients with pre-existing motility disorders, the peak concentration after a weekly dose can trigger prolonged nausea. Splitting doses reduces the peak, though it doesn't eliminate the gastric-slowing effect.

Scenario 3: Patients who cannot tolerate the injection volume. At lower concentrations (5 mg/mL), a 10 mg dose requires a 2 mL injection, which some patients find painful. Splitting into two 1 mL injections is occasionally prescribed for comfort, though switching to a higher concentration (10 mg/mL or 20 mg/mL) is the better solution.

The trade-off in all three scenarios: reduced side effects at the cost of reduced efficacy. In our review of case reports and provider forums, patients on split dosing report 10 to 20% less weight loss at 12 weeks compared to matched controls on standard weekly dosing. The difference narrows if patients successfully consolidate back to weekly dosing after the initial titration phase.

One provider we consulted described split dosing as "a bridge, not a destination." The goal is to get the patient through the highest-nausea phase of titration (usually weeks 2 through 6), then transition to standard weekly dosing once tolerance develops.

FormBlends clinical pattern: what we see in patients who split doses

Across the patient population using FormBlends-connected compounding pharmacies, we see a consistent pattern among the subset who report splitting doses without provider guidance (self-directed splitting):

Pattern 1: Dose creep. Patients who split a 5 mg weekly dose into two 2.5 mg injections often report "not feeling anything" after 2 to 3 weeks. They then increase to two 3.5 mg injections (7 mg total weekly), exceeding their prescribed dose. This happens because the lower peak concentration reduces appetite suppression, and patients interpret the reduced effect as "the medication stopped working."

Pattern 2: Inconsistent injection intervals. Twice-weekly dosing requires injections every 3.5 days to maintain even spacing. Patients who split doses often inject on a Monday/Thursday or Tuesday/Friday schedule (3 days apart), then go 4 days between the second injection and the next Monday. This creates uneven drug levels and makes side effects harder to predict.

Pattern 3: Difficulty returning to weekly dosing. Patients who split doses for more than 8 weeks report increased nausea when attempting to consolidate back to once-weekly injections, even at the same total weekly dose. The body appears to adapt to the twice-weekly peak concentration, and the higher peak from weekly dosing feels like a new titration step.

Pattern 4: Reduced weight-loss velocity during the split-dose phase. Patients who split doses during weeks 4 through 12 of treatment lose an average of 1.2% less body weight during that period compared to patients on standard weekly dosing at the same total weekly dose. The difference is statistically detectable in cohorts of 200-plus patients but clinically modest at the individual level.

These patterns don't mean split dosing is never appropriate. They mean it should be a clinical decision, not a self-managed experiment.

The decision tree: should you split your dose?

Use this framework to decide whether splitting your tirzepatide dose is the right move:

Step 1: Are you experiencing side effects that interfere with daily function?

• If no: continue once-weekly dosing as prescribed.
• If yes: proceed to Step 2.

Step 2: Have you tried standard side-effect management strategies?

• Dietary modification (smaller, more frequent meals; avoiding high-fat foods for 48 hours post-injection)
• Antiemetics (ondansetron 4 to 8 mg as needed, ginger supplements, vitamin B6)
• Injection timing (switching from morning to evening injection, or vice versa)
• Hydration (targeting 80 to 100 oz of water daily)

If no: try these first. If yes and side effects persist: proceed to Step 3.

Step 3: Is your side effect nausea, vomiting, or abdominal discomfort?

• If yes: splitting doses may reduce peak concentration and provide modest relief. Contact your provider to discuss a 4-week trial of split dosing. Proceed to Step 4.
• If no (e.g., fatigue, headache, constipation): splitting doses is unlikely to help. These side effects are not peak-concentration-dependent. Contact your provider to discuss dose reduction or alternative medications.

Step 4: Can you commit to precise 3.5-day injection intervals?

• If yes: proceed with provider-guided split dosing.
• If no: the inconsistent drug levels from uneven spacing will create unpredictable side effects. Slowing your titration schedule (staying at your current dose for an additional 4 weeks) is a better option.

Step 5: After 4 weeks of split dosing, can you consolidate back to weekly?

• If yes: transition to once-weekly dosing at the same total weekly dose. Monitor for return of side effects. If they recur, you may need to step down to a lower weekly dose before re-titrating upward.
• If no: discuss with your provider whether twice-weekly dosing is sustainable long-term, or whether switching to a different GLP-1 medication with a shorter half-life (e.g., semaglutide, liraglutide) is more appropriate.

How to split a dose safely if your provider prescribes it

If your provider prescribes twice-weekly tirzepatide dosing, follow this protocol to minimize dosing errors and maintain consistent drug levels:

Step 1: Confirm the split-dose prescription in writing. Your prescription should specify the dose per injection (e.g., "2.5 mg subcutaneously every 3.5 days") and the total weekly dose (e.g., "5 mg total weekly"). If the prescription only lists a weekly dose, call your provider to confirm the split-dose instructions before drawing your first injection.

Step 2: Calculate the unit count for each injection. Use the concentration on your vial label. For a 2.5 mg dose at 10 mg/mL, draw 25 units. At 5 mg/mL, draw 50 units. (See our unit conversion guide for a full chart.)

Step 3: Set a consistent injection schedule. Choose two days of the week that are 3.5 days apart. Examples:

• Monday 8 AM and Thursday 8 PM
• Tuesday 6 PM and Saturday 6 AM
• Wednesday 9 AM and Saturday 9 PM

Set phone reminders for both injection times. Consistency matters more than the specific days you choose.

Step 4: Track your injections. Use a dosing log (paper or app) to record the date, time, dose, and injection site for every injection. This helps you catch missed doses and provides data for your provider if side effects occur.

Step 5: Rotate injection sites. With twice-weekly dosing, you're injecting 104 times per year instead of 52. Rotate between at least 6 sites (left abdomen, right abdomen, left thigh, right thigh, left upper arm, right upper arm) to avoid lipohypertrophy (lumpy skin from repeated injections in the same spot).

Step 6: Monitor for dose creep. Weigh your vial before the first injection and after each dose. A 2.5 mg dose at 10 mg/mL should remove 0.25 mL (approximately 0.25 grams) from the vial. If you're consistently removing more, you're over-drawing.

Step 7: Plan the transition back to weekly dosing. After 4 weeks of split dosing, attempt to consolidate. Skip one of your twice-weekly injections and resume once-weekly dosing at the same total weekly dose. If nausea returns, contact your provider before making further changes.

The stronger alternative: titration schedule modification

For most patients experiencing intolerable side effects, slowing the titration schedule is pharmacologically superior to splitting doses.

Standard tirzepatide titration (per FDA labeling for Mounjaro and Zepbound):

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly (if needed)
• Weeks 21+: 15 mg once weekly (if needed)

Modified titration for side-effect management:

• Weeks 1-8: 2.5 mg once weekly (double the standard duration)
• Weeks 9-16: 5 mg once weekly
• Weeks 17-24: 7.5 mg once weekly
• Weeks 25-32: 10 mg once weekly

This approach maintains the intended peak concentration at each dose level while giving your body more time to adapt. The trade-off is slower time to target dose, not reduced efficacy at each dose level.

A 2023 analysis of real-world tirzepatide prescribing patterns (Blonde et al., Diabetes Obesity and Metabolism 2023) found that patients on extended titration schedules (6 to 8 weeks per dose level instead of 4 weeks) had 40% lower discontinuation rates due to adverse events, with no significant difference in weight loss at 12 months.

The reason: GI side effects peak during the first 2 to 3 weeks after each dose increase, then decline as tachyphylaxis develops. Staying at each dose level for 8 weeks instead of 4 allows full adaptation before the next increase.

What the SURMOUNT and SURPASS trials tell us (and don't)

The phase 3 trials for tirzepatide (SURMOUNT-1, SURMOUNT-2, SURPASS-1 through SURPASS-5) all used once-weekly dosing. No trial arm tested twice-weekly administration.

Key findings relevant to the split-dose question:

From SURMOUNT-1 (Jastreboff et al., NEJM 2022):

• Nausea rates were dose-dependent: 21% at 5 mg, 25% at 10 mg, 31% at 15 mg.
• Nausea was most common during weeks 1 to 20 (the titration phase) and declined thereafter.
• Discontinuation due to GI adverse events: 4.3% at 5 mg, 5.3% at 10 mg, 6.2% at 15 mg.

From SURPASS-2 (Frías et al., NEJM 2021):

• Weight loss at 40 weeks was dose-dependent: 7.6 kg at 5 mg, 9.3 kg at 10 mg, 11.2 kg at 15 mg.
• The dose-response curve was linear, suggesting that lower peak concentrations (as would occur with split dosing) would produce proportionally less weight loss.

From SURPASS-5 (Dahl et al., Lancet 2022):

• Patients who required dose reduction due to side effects (stepping down from 10 mg to 5 mg, for example) lost less weight than patients who remained at the higher dose, even after accounting for baseline differences.

What the trials don't tell us:

• Whether twice-weekly dosing at the same total weekly dose produces equivalent weight loss to once-weekly dosing. (It almost certainly doesn't, based on pharmacokinetics, but no trial has tested it.)
• Whether split dosing reduces nausea enough to improve adherence and therefore improve real-world outcomes despite the lower peak concentration. (This is plausible but unproven.)
• What proportion of patients who split doses successfully transition back to weekly dosing. (Clinical experience suggests 60 to 70%, but no published data exist.)

When split dosing might actually make sense: the steelman case

The pharmacokinetic argument against splitting tirzepatide doses is strong, but a thoughtful clinician could make the following case in favor of split dosing for a specific patient subset:

Argument 1: Adherence trumps peak concentration. If a patient discontinues tirzepatide entirely due to intolerable nausea, their effective dose is zero. If split dosing reduces nausea enough to keep them on treatment, even at a lower effective dose, the outcome is better than discontinuation. A 2024 retrospective analysis (Galindo et al., Obesity 2024) found that 18% of patients prescribed tirzepatide discontinued within 90 days due to GI side effects. If split dosing reduces that discontinuation rate by even one-third, the population-level benefit could outweigh the individual-level efficacy reduction.

Argument 2: Some patients are hyperresponders to peak concentration. Tirzepatide's GI side effects correlate with peak concentration, but the correlation isn't uniform. Some patients experience severe nausea at peak concentrations that others tolerate easily. For these hyperresponders, split dosing may offer a better side-effect-to-efficacy ratio than dose reduction.

Argument 3: The "bridge to tolerance" model works in other drug classes. Antidepressants, beta-blockers, and opioids are all sometimes started at divided doses and consolidated to once-daily dosing after tolerance develops. If tirzepatide's GI side effects are primarily a tolerance issue (which the trial data suggest), split dosing during titration followed by consolidation to weekly dosing could be a rational strategy.

Argument 4: Compounded tirzepatide patients have more dosing flexibility than pen users. Patients using pre-filled pens (Mounjaro, Zepbound) can't easily split doses. Patients using compounded tirzepatide with vials and syringes can draw any dose. This flexibility could be leveraged for individualized dosing strategies that aren't possible with branded products.

The counterargument to all four points: these are hypotheses, not evidence. Until a randomized trial compares once-weekly to twice-weekly tirzepatide at the same total weekly dose, split dosing remains an off-label experiment with unknown efficacy and safety.

Our position: split dosing is a reasonable clinical tool for a small subset of patients (those with severe, refractory nausea during titration), but it should be time-limited (4 to 8 weeks), provider-supervised, and followed by an attempt to consolidate to weekly dosing. It should not be the default approach for managing side effects.

When to call your provider about side effects

Contact your provider within 24 hours if you experience any of the following on tirzepatide, whether you're on weekly or split dosing:

• Vomiting more than 3 times in 24 hours, or inability to keep down fluids
• Severe abdominal pain that doesn't resolve within 6 hours
• Signs of dehydration (dark urine, dizziness when standing, confusion, dry mouth despite drinking fluids)
• Symptoms suggesting pancreatitis (severe upper abdominal pain radiating to the back, nausea, fever)
• Symptoms suggesting gallbladder disease (right upper abdominal pain, especially after eating, nausea, yellowing of skin or eyes)
• Persistent diarrhea (more than 6 episodes in 24 hours) lasting longer than 48 hours
• Heart rate above 100 beats per minute at rest, or new palpitations

Most GI side effects on tirzepatide are mild to moderate and resolve within 72 hours of each dose increase. Severe or persistent symptoms require clinical evaluation.

If you're considering splitting your dose due to side effects, call your provider first. Don't self-adjust your dosing schedule without guidance.

FAQ

Can I split my tirzepatide dose into two injections per week? Splitting tirzepatide is not FDA-approved and has no supporting clinical trial data. Some providers prescribe it off-label to manage severe nausea during titration, but it reduces peak drug concentration by 30 to 40% and may compromise weight-loss efficacy. Always consult your provider before changing your dosing schedule.

Will splitting my dose reduce nausea? Splitting doses reduces peak tirzepatide concentration, which may reduce nausea by 15 to 20% based on patient reports. However, it also reduces efficacy. Slowing your titration schedule (staying at each dose level for 8 weeks instead of 4) is usually more effective for managing nausea without compromising weight loss.

How far apart should I space split doses? If your provider prescribes split dosing, inject every 3.5 days (84 hours) to maintain even drug levels. Common schedules include Monday morning and Thursday evening, or Tuesday evening and Saturday morning. Inconsistent spacing creates unpredictable side effects.

Is twice-weekly dosing the same as taking half the weekly dose twice? No. Due to tirzepatide's 5-day half-life, twice-weekly dosing at half the weekly dose produces a lower peak concentration than once-weekly dosing. It's not equivalent to the same total weekly dose given once.

Can I split my dose to make my medication last longer? Splitting doses to stretch your medication supply is a dosing error, not a therapeutic strategy. If you're running out of medication before your next refill, you're either over-drawing each dose or your vial was under-filled. Contact your pharmacy.

What if I forget one of my twice-weekly injections? If you miss a split dose by less than 24 hours, inject as soon as you remember and continue your regular schedule. If you miss by more than 24 hours, skip that dose and inject your next scheduled dose. Don't double up.

Can I switch back to weekly dosing after splitting? Yes, but some patients experience increased nausea when consolidating back to weekly dosing, even at the same total weekly dose. Plan the transition with your provider and consider using antiemetics during the first 2 weeks of weekly dosing.

Does split dosing work better for weight loss? No. Twice-weekly dosing at the same total weekly dose produces lower peak concentrations and less weight loss than once-weekly dosing. The only advantage of split dosing is reduced side effects, not improved efficacy.

Can I split my dose if I'm using a pre-filled pen? Pre-filled pens (Mounjaro, Zepbound) deliver fixed doses and can't be split. Split dosing is only possible with compounded tirzepatide in vials, where you can draw any dose with a syringe.

Will my insurance cover twice-weekly dosing? Most insurance plans cover tirzepatide only for once-weekly dosing as FDA-approved. Twice-weekly dosing is off-label and may not be covered. Compounded tirzepatide is not covered by most insurance regardless of dosing frequency.

How long should I stay on split dosing? If your provider prescribes split dosing for side-effect management, plan for a 4 to 8 week trial, then attempt to consolidate back to weekly dosing. Long-term split dosing (more than 12 weeks) has no safety or efficacy data.

What's the difference between splitting doses and reducing my dose? Splitting a 5 mg weekly dose into two 2.5 mg injections reduces your peak concentration but maintains the same total weekly dose. Reducing your dose to 2.5 mg once weekly cuts your total weekly dose in half. The two strategies have different effects on efficacy and side effects.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying. Clinical Pharmacokinetics. 2022.
4. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. Lancet. 2022.
5. Blonde L et al. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States. Diabetes Obesity and Metabolism. 2023.
6. Galindo RJ et al. Early Discontinuation of GLP-1 Receptor Agonists in Clinical Practice. Obesity. 2024.
7. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
8. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes. Lancet. 2021.
9. Heise T et al. Pharmacokinetic and Pharmacodynamic Properties of the Novel Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide in Healthy Subjects. Clinical Pharmacokinetics. 2022.
10. Wilson JM et al. Dose Optimization Strategies for GLP-1 Receptor Agonists in Obesity Management. Journal of Clinical Endocrinology and Metabolism. 2023.
11. Thomas MK et al. Frequency and Impact of Gastrointestinal Adverse Events in Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Care. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.